<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308463">
  <stage>Registered</stage>
  <submitdate>14/01/2010</submitdate>
  <approvaldate>6/02/2006</approvaldate>
  <actrnumber>ACTRN12610000071022</actrnumber>
  <trial_identification>
    <studytitle>A multicenter open label study to compare efficacy and safety of induction treatment by ATG (thymoglobulin) versus anti-IL-2R (daclizumab) with a triple drug regimen (tacrolimus, mycophenolate mofetil, prednisone) in high risk renal transplant recipients.</studytitle>
    <scientifictitle>A multicenter open label study to compare efficacy and safety of induction treatment by thymoglobulin (ATG) versus daclizumab (anti-IL-2R) with a triple drug regimen (tacrolimus, mycophenolate mofetil, prednisone) in high risk renal transplant recipients.</scientifictitle>
    <utrn />
    <trialacronym>TAXI</trialacronym>
    <secondaryid>Cochrane Renal Group 020600038</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Incidence of acute rejection in renal transplantation</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>daclizumab: 1 mg/kg (intravenous [IV] infusion) at days 0, 14, 28, 42 and 56 post transplant.</interventions>
    <comparator>thymoglobulin: 1.25 mg/kg (once daily, IV infusion) from day 0 to 7 post transplant</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of biopsy-proven acute allograft rejection</outcome>
      <timepoint>12 months post transplant</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of patients who experienced an acute rejection episode, whether confirmed by biopsy or not (serum creatinine increase, reversed after antirejection treatment) at 1 year.</outcome>
      <timepoint>12 months post transplant</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of patients who experienced more than one episode of acute allograft rejection.</outcome>
      <timepoint>12 months post transplant</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of patients who experienced an acute rejection episode that required therapy by anti-lymphocyte antibodies (ATG or anti-CD3 monoclonal antibodies).</outcome>
      <timepoint>12 months post transplant</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Banff grade of the first rejection episode.</outcome>
      <timepoint>12 months post transplant</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of adverse events in the two treatment arms at 1 year.
- leukopenia, anemia, thombopenia (weekly blood samples)
- infections: bacterial infections, cytomegalovirus, BK virus, pneumocystosis (blood or urine samples when clinical symptoms occurred)
- Post Transplant Lymphoproliferative Disorders</outcome>
      <timepoint>12 months post transplant</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of delayed graft function defined as the need for hemodialysis within the first week post graft</outcome>
      <timepoint>12 months post transplant</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Graft function: serum creatinine and estimated glomerular filtration rate (GFR) calculated with the abbreviated Modification of the Diet in Renal Disease (aMDRD) and Cockcroft formulas.</outcome>
      <timepoint>12 months post transplant</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Graft survival (date of graft failure is the date when dialysis was restarted)</outcome>
      <timepoint>12 months post transplant</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patient survival (date of event is the date when the patient died)</outcome>
      <timepoint>12 months post transplant</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients candidate for renal transplantation who fulfill the following criteria: 

1) Third or fourth renal graft or

2) Current anti-Human Leukocyte Antigen (HLA) antibodies above or equal to 30% at the last evaluation or

3) Peak anti-HLA antibodies above or equal to 50% at the last evaluation or

4) A second graft if the first was lost within 2 years because of rejection.

5) Patients who gave their informed consent and are able to understand the scope of the study</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1) Transplantation from living donors or recipients of multiple grafts or patients who already have received another (non-renal) allograft.

2)Transplantation from a non-heart beating donor

3) Transplantation of two kidneys from the same donor

4) Patients with generalized infection at the time of transplantation

5) Women in child-bearing age who do not plan to use efficient contraception</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>13/05/2001</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>240</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>France</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Centre Hospitalier Regional Universitaire (CHRU) de Lille</primarysponsorname>
    <primarysponsoraddress>Centre Hospitalier Regional Universitaire de Lille
rue Michel Polonowski
59000
Lille</primarysponsoraddress>
    <primarysponsorcountry>France</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Regional Hospital of Lille</fundingname>
      <fundingaddress>Centre Hospitalier Regional Universitaire de Lille
rue Michel Polonowski
59000
Lille</fundingaddress>
      <fundingcountry>France</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of this study was to compare the incidence of acute rejection in de novo renal transplant recipients with a high immunological risk who received either thymoglobulin or daclizumab induction.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Prof, Marc, HAZZAN</name>
      <address>Nephrology Department, Hopital Huriez - CHRU Lille, 59037 Lille Cedex</address>
      <phone>+33 3 20 44 67 70</phone>
      <fax>+33 3 20 44 58 72</fax>
      <email>mhazzan@gmail.com</email>
      <country>France</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Prof, Christian, Noel</name>
      <address>Head, Nephrology Department, Hopital Huriez - CHRU Lille, 59037 Lille Cedex</address>
      <phone>+33 320 44 41 42</phone>
      <fax />
      <email>christian.noel@CHRU-Lille.fr</email>
      <country>France</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Prof, Marc, HAZZAN</name>
      <address>Nephrology Department, Hopital Huriez - CHRU Lille, 59037 Lille Cedex</address>
      <phone>+33 3 20 44 67 70</phone>
      <fax>+33 3 20 44 58 72</fax>
      <email>mhazzan@gmail.com</email>
      <country>France</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>